



Optibrium and Goldfinch Bio Sign Agreement for StarDrop License

Goldfinch Bio's researchers select StarDrop to guide successful drug discovery

CAMBRIDGE, UK and Cambridge, MA, USA, 9th May 2017 – Optibrium, a developer of software for small molecule discovery, and Goldfinch Bio, a company focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that the company has signed a multi-year agreement to license Optibrium's StarDrop software. The agreement will see the deployment of six of StarDrop's plug-in modules and implementation of StarDrop's Query Interface for seamless integration with Goldfinch Bio's chemistry and biology databases.

StarDrop is a complete package of fully integrated software for small molecule design, optimisation and data analysis. With a highly visual and user-friendly interface it enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency and productivity of the drug discovery process. Seamlessly connecting with other models, informatics methods and databases, StarDrop provides user-friendly access to resources making project management quicker and simpler.

Dr Matthew Segall, Optibrium's CEO, commented: "We are delighted to welcome Goldfinch Bio to the family of StarDrop users. We look forward to working with their scientists to support their use of StarDrop in the discovery of new precision therapies for kidney disease."

Dr Thomas Tibbitts, VP of Computational Discovery at Goldfinch, commented: "We chose StarDrop as a platform to extend our use of *in silico* methods for prioritisation of high quality compounds and design of the next iteration for synthesis and testing. Its seamless integration and user friendly interface makes these approaches accessible to all of our project team."

For further information on Optibrium and StarDrop, please visit www.optibrium.com/stardrop/, contact info@optibrium.com or call +44 1223 815900.

ENDS

Media contact

Sarah Jeffery

Zyme Communications

E-mail: sarah.jeffery@zymecommunications.com

Phone: +44 (0) 7771 730919

Optibrium

Nick Foster

Head of Commercial Operations

E-mail: nick.foster@optibrium.com

Phone: +44 (0)1223 815900

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. The company's lead product, StarDrop, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston, US. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit www.optibrium.com or join in discussions on improving the productivity of drug discovery at www.optibrium.com/community.

About Goldfinch Bio

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.